The startups we track
Venture-backed UK startups at Series A and beyond, with their funding and how many roles they have open today.
43 companies
| Company | Sector | Latest round | HQ | Open roles |
|---|---|---|---|---|
 Flo Health Femtech / women's health app. Sponsors visas | Health & Life Sciences | Series C $200m, 2024-07 | London | 33 |
 Scarlet AI medical device certification (notified body) | Health & Life Sciences | Series B $50M, 2026-10 | London | 18 |
 Numan Digital health / men's and weight health. Sponsors visas | Health & Life Sciences | Series B $60m ($30m equity + growth capital), 2025-07 | London | 16 |
 Basecamp Research AI drug discovery / techbio. Sponsors visas | Health & Life Sciences | Series C $140m, 2026-09 | London | 14 |
 Accurx Primary care communication software. Sponsors visas | Health & Life Sciences | Series B $38m (£27.5m), 2021-09 | London | 12 |
 CoMind Neurotechnology / medtech. Sponsors visas | Health & Life Sciences | Series A $60M (£45M), 2025-10 | London | 10 |
 Semble Healthcare practice management software | Health & Life Sciences | Series C £30m, 2026-06 | London | 10 |
 Cellular Origins Cell therapy manufacturing automation | Health & Life Sciences | Series A €34.2M, 2025-12 | Cambridge | 8 |
 Doccla Virtual wards / remote monitoring. Sponsors visas | Health & Life Sciences | Series B £35m ($46m), 2024-09 | London | 7 |
 Latent Labs AI protein design / techbio. Sponsors visas | Health & Life Sciences | Series A $40m, 2025-02 | London | 7 |
 Limbic Mental health AI. Sponsors visas | Health & Life Sciences | Series A $14m, 2024-03 | London | 7 |
 Simple Digital health / weight and fasting app. Sponsors visas | Health & Life Sciences | Series A £26M, 2025-10 | London | 6 |
 Automata Lab automation / AI-ready labs. Sponsors visas | Health & Life Sciences | Series C $45m, 2026-01 | London | 5 |
 Qureight AI medical imaging for clinical trials | Health & Life Sciences | Series B £15m ($20m), 2026-07 | Cambridge | 5 |
 Engitix Biotech / extracellular matrix drug discovery. Sponsors visas | Health & Life Sciences | Series A £20M Series A extension, 2026-01 | London | 4 |
 Lindus Health Clinical trials / CRO tech. Sponsors visas | Health & Life Sciences | Series B $55m, 2025-01 | London | 4 |
 01Health Digital health / specialist care platform | Health & Life Sciences | Series A $15m (£11.2m), 2026-06 | London | 3 |
 SheMed Women's health / GLP-1 weight management. Sponsors visas | Health & Life Sciences | Series A $50M, 2025-10 | London | 3 |
 Skin Analytics AI dermatology / medtech. Sponsors visas | Health & Life Sciences | Series B £15m, 2025-04 | London | 3 |
 Constructive Bio Synthetic biology / biotech. Sponsors visas | Health & Life Sciences | Series A $58m, 2024-09 | Cambridge | 2 |
 Alchemab Therapeutics AI drug discovery / antibodies. Sponsors visas | Health & Life Sciences | Series A £25m (~$34m), 2026-07 | Cambridge | 1 |
 Antiverse AI antibody discovery. Sponsors visas | Health & Life Sciences | Series A $9.3M (£7M), 2026-03 | Cardiff | 1 |
Evaro Embedded digital health / e-prescribing | Health & Life Sciences | Series A $25M (£18.3M), 2026-01 | Norwich | 1 |
 Healx AI drug discovery (rare disease). Sponsors visas | Health & Life Sciences | Series C $47m, 2024-08 | Cambridge | 1 |
 IMU Biosciences Immune profiling diagnostics | Health & Life Sciences | Series A £40m ($53m), 2026-06 | London | 1 |
 OMass Therapeutics Biotech / small-molecule drug discovery | Health & Life Sciences | Series C $310M (£233.8m), 2026-10 | Oxford | 1 |
adsilico AI simulation of medical devices on virtual patients | Health & Life Sciences | Series A £10m, 2026-10 | Leeds | not tracked |
 Artios Pharma Biotech / DNA damage response oncology. Sponsors visas | Health & Life Sciences | Series D+ $115M (£87M), 2025-11 | Cambridge | not tracked |
 bit.bio Synthetic biology / cell programming. Sponsors visas | Health & Life Sciences | Series C $50M, 2026-01 | Cambridge | 0 |
 Brainomix AI medical imaging. Sponsors visas | Health & Life Sciences | Series C £4.8M Series C extension, 2026-02 | Oxford | 0 |
 CellCentric Biotech / oncology | Health & Life Sciences | Series D+ $220m (~£162m), 2026-05 | Cambridge | not tracked |
 Cera Home healthcare / AI care platform. Sponsors visas | Health & Life Sciences | Growth $150m, 2025-01 | London | not tracked |
 Cytospire Therapeutics Biotech / immuno-oncology. Sponsors visas | Health & Life Sciences | Series A £61m ($83m), 2026-05 | London | not tracked |
 Flok Health Digital MSK / AI physiotherapy. Sponsors visas | Health & Life Sciences | Series A $12.5m (~£9.3m), 2026-06 | Cambridge | not tracked |
 Hypervision Surgical Medtech / surgical imaging. Sponsors visas | Health & Life Sciences | Series A £17m, 2026-04 | London | not tracked |
 Mestag Therapeutics Biotech / immuno-oncology & fibrosis. Sponsors visas | Health & Life Sciences | Growth $40M, 2026-03 | Cambridge | not tracked |
 Microbiotica Microbiome therapeutics | Health & Life Sciences | Series C £36m (first close), 2026-10 | Cambridge | not tracked |
 PolyModels Hub AI/modelling software for pharma process development | Health & Life Sciences | Series A £7M, 2025-11 | London | 0 |
 RQ Bio Biotech / antibodies. Sponsors visas | Health & Life Sciences | Series A £85.5m ($115m), 2026-06 | London | not tracked |
 Sava Wearable biosensors / glucose monitoring | Health & Life Sciences | Series B €32.1m, 2026-10 | London | not tracked |
Sensible Biotechnologies mRNA manufacturing in cells | Health & Life Sciences | Series A $47M (incl. up to $20m non-dilutive), 2026-10 | Oxford | not tracked |
 T-Therapeutics Biotech / TCR bispecific immunotherapies. Sponsors visas | Health & Life Sciences | Series A £24M extension (Series A total $91M), 2025-11 | Cambridge | not tracked |
 TidalSense Respiratory diagnostics. Sponsors visas | Health & Life Sciences | Series B £14.2m ($19m), 2026-07 | Cambridge | 0 |